Assembly Biosciences, Inc. (ASMB)

Market Cap	96.68M
Revenue (ttm)	28.33M
Net Income (ttm)	-40.80M
Shares Out	6.36M
EPS (ttm)	-7.16
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	30,654
Open	15.70
Previous Close	15.81
Day's Range	15.00 - 16.26
52-Week Range	9.12 - 19.93
Beta	0.56
Analysts	Buy
Price Target	35.00 (+130.11%)
Earnings Date	Nov 7, 2024

About ASMB

Assembly Biosciences, Inc., a biotechnology company, develops therapeutic candidates for the treatment of viral diseases. It develops ABI-5366, a long-acting herpes simplex virus (HSV) helicase-primase inhibitor that is in Phase 1a/1b clinical trial to treat recurrent genital herpes; ABI-1179, which is in Phase 1a/1b clinical trial for the treatment of recurrent genital herpes; and ABI-6250, a small molecule orally bioavailable hepatitis delta virus entry inhibitor that is in Phase 1a clinical trial. The company also develops ABI-4334, a next-g...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Dec 17, 2010
• Employees: 65
• Stock Exchange: NASDAQ
• Ticker Symbol: ASMB
• Website: https://www.assemblybio.com

Analyst Forecast

According to 2 analysts, the average rating for ASMB stock is "Buy." The 12-month stock price forecast is $35.0, which is an increase of 130.11% from the latest price.

Price Target

$35.0

(130.11% upside)

Analyst Consensus: Buy